Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | GRAMD1A | Q96CP6 | 5/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.51 |
| ▸ | STAT3 | P40763 | 3/20 | 0.50 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | CASK | O14936 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.48 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.48 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773874 | 0.83 | EGFR (0.60) | CRBNDDB1EGFRERBB2BRD9 | |
| SCHEMBL20120827 | 0.83 | EGFR (0.60) | CRBNDDB1EGFRERBB2BRD9 | |
| SCHEMBL20120562 | 0.82 | BRD9 (0.46) | CRBNDDB1BRD9 | |
| SCHEMBL29547736 | 0.82 | BRD9 (0.46) | CRBNDDB1BRD9 | |
| SCHEMBL20120403 | 0.82 | CRBN (0.53) | CRBNEGFRERBB2BRD9STAT3 | |
| SCHEMBL24220561 | 0.80 | CRBN (0.70) | CRBNDDB1GRAMD1AEGFRERBB2 | |
| SCHEMBL20233752 | 0.79 | EGFR (0.56) | CRBNDDB1EGFRERBB2BRD9 | |
| SCHEMBL31716521 | 0.79 | CRBN (0.62) | CRBNDDB1GRAMD1ASTAT3BRD4 | |
| SCHEMBL31715969 | 0.79 | CRBN (0.62) | CRBNDDB1GRAMD1ASTAT3BRD4 | |
| SCHEMBL31716466 | 0.79 | CRBN (0.62) | CRBNDDB1GRAMD1ASTAT3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CRBN 3/4885DDB1 433/4885GRAMD1A 2819/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | CRBN 1/4885DDB1 473/4885GRAMD1A 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.